Drug Resistance Screening
Drug Resistance Screening - Related Videos
05:46
Rapid Screening of HIV Reverse Transcriptase and Integrase Inhibitors
0 Views •
Cited by 15 •
2014
Here we describe cellular cytotoxicity and single round infectivity assays that allow for the rapid and accurate screening of compounds to determine their cellular cytotoxicity (CC50) and IC50 values against WT and drug resistant HIV-1.
08:46
Implementation of In Vitro Drug Resistance Assays: Maximizing the Potential for Uncovering Clinically Relevant Resistance Mechanisms
0 Views •
Cited by 2 •
2015
Drug resistance to targeted therapeutics is widespread and the need to identify mechanisms of resistance--prior to or following clinical onset--is critical for guiding alternative clinical management strategies. Here, we present a protocol to couple derivation of drug-resistant lines in vitro with sequencing to expedite discovery of these mechanisms.
02:30
Seedling Flood Assay for Screening Bacterial Resistance in Tomatoes
0 Views •
2025
Source: Hassan, J. A., et al. High-Throughput Identification of Resistance to Pseudomonas syringae pv. Tomato in Tomato using Seedling Flood Assay. J. Vis. Exp. (2020).This video demonstrates a method to screen for bacterial resistance in different tomato strains using ten-day-old seedlings inoculated with a bacterial suspension. It explains how bacteria invade through stomata, deliver effector proteins to suppress plant immunity, and how plant responses differ between susceptible and resistant...
11:56
Nanomechanics of Drug-target Interactions and Antibacterial Resistance Detection
0 Views •
Cited by 4 •
2013
Acquired resistance to antibiotics is a major public healthcare problem and is presently ranked by the WHO as one of the greatest threats to human life. Here we describe the use of cantilever technology to quantify antibacterial resistance, critical to the discovery of novel and powerful agents against multidrug resistant bacteria.
14:51
Pooled shRNA Library Screening to Identify Factors that Modulate a Drug Resistance Phenotype
0 Views •
Cited by 2 •
2022
High-throughput RNA interference (RNAi) screening using a pool of lentiviral shRNAs can be a tool to detect therapeutically relevant synthetic lethal targets in malignancies. We provide a pooled shRNA screening approach to investigate the epigenetic effectors in acute myeloid leukemia (AML).
FAQs
A dose-response design compares cellular or microbial behavior across defined drug concentrations rather than relying on a single exposure level. Researchers measure growth, viability, or another response at each concentration and examine how strongly treatment suppresses the sample. Survival or continued growth at concentrations that affect more sensitive samples indicates reduced sensitivity and helps distinguish gradual responses from pronounced resistance.
Genetic analysis can connect a reduced response with mutations or biological pathways associated with resistance. The screening result first identifies samples that remain less affected by treatment, while subsequent analysis investigates possible genetic explanations. This combination links an observable phenotype with underlying biology, supporting studies of how resistance develops and which mechanisms may reduce therapeutic effectiveness.
Phenotypic screening shows what happens after exposure by measuring growth, viability, or another dose-dependent response. Genetic analysis addresses why that response may occur by identifying mutations or pathways associated with reduced sensitivity. Using both approaches provides a more complete view than either alone, because researchers can relate treatment survival to potential biological mechanisms.
Growth and viability provide different ways to evaluate how a sample responds to treatment, while other dose-dependent measurements may capture additional effects. The appropriate readout depends on whether the experiment focuses on continued proliferation, survival, or another measurable response. Comparing results across drug concentrations helps researchers characterize the strength and pattern of reduced sensitivity.
A typical workflow begins by exposing cells, microorganisms, or tumor samples to defined concentrations of a therapeutic compound. Researchers then measure growth, viability, or another response across those conditions and compare the results among samples or compounds. Samples showing reduced sensitivity can undergo genetic analysis to investigate mutations or pathways linked to the observed outcome.
The approach supports antimicrobial susceptibility testing, cancer research, and drug development. It can help compare compounds, identify treatments that retain activity against particular samples, and investigate why some cells or microorganisms respond poorly. Repeated screening also provides a way to monitor emerging resistance, which is important when reduced sensitivity could eventually limit therapeutic effectiveness.